通过小干扰 RNA (siRNA) 进行基因沉默是调节癌症死亡、肿瘤复发或转移的一种有吸引力的疗法。由于siRNA很容易被降解，因此有必要开发运输和递送系统以实现有效的肿瘤靶向。自纳米乳化系统 (SNEDDS) 已成功用于 pDNA 运输和递送，因此它们可能对 siRNA 有用。本工作的目的是将 siRNA-RAD51 引入由 Phospholipon-90G、Labrafil-M1944-CS 和 Cremophor-RH40 制备的 SNEDDS 中，并评估其预防光动力疗法 (PDT) 引起的 DNA 双链断裂同源重组的功效使用壳聚糖将siRNA-RAD51加载到SNEDDS中。通过与 Lipofectamine-2000 进行比较来估计转染能力。SNEDDS(siRNA-RAD51) 诱导基因沉默对治疗的效果通过使用 T47D 乳腺癌细胞的细胞活力和克隆形成测定进行评估。SNEDDS(siRNA-RAD51) 被证明是一种有效的 siRNA-降低 PDT 或 IR 细胞耐药性的递送系统。版权所有 © 2024 国际细胞学会

Gene-silencing by small interfering RNA (siRNA) is an attractive therapy to regulate cancer death, tumor recurrence or metastasis. Because siRNAs are easily degraded, it is necessary to develop transport and delivery systems to achieve efficient tumor targeting. Self-nanoemulsifying systems (SNEDDS) have been successfully used for pDNA transport and delivery, so they may be useful for siRNA. The aim of this work is to introduce siRNA-RAD51 into a SNEDDS prepared with Phospholipon-90G, Labrafil-M1944-CS and Cremophor-RH40 and evaluate its efficacy in preventing homologous recombination of DNA double-strand breaks caused by photodynamic therapy (PDT) and ionizing radiation (IR).The siRNA-RAD51 was loaded into SNEDDS using chitosan. Transfection capacity was estimated by comparison with Lipofectamine-2000.SNEDDS(siRNA-RAD51) induced gene silencing effect on the therapies evaluated by cell viability and clonogenic assays using T47D breast cancer cells.SNEDDS(siRNA-RAD51) shown to be an effective siRNA-delivery system to decrease cellular resistance in PDT or IR.Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.